{"corpus_id":1215691,"paper_sha":"b5523c34aceaf17051ae0bbbdfcf7f98e3b12b98","doi":"10.1007/s00415-013-7169-7","arxiv_id":null,"pmid":24272588,"pmcid":"3895189","mag_id":2038941725,"dblp_id":null,"acl_id":null,"title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","year":2013,"publication_date":"2013-11-23","venue":"Journal of Neurology","journal":{"name":"Journal of Neurology","pages":"1 - 16","volume":"261"},"journal_issn":null,"journal_title":null,"publication_types":["Review","JournalArticle"],"pubmed_pub_types":["Journal Article","Review"],"s2_fields_of_study":["Medicine"],"reference_count":242,"citation_count":568,"influential_citation_count":23,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Diagnosis-Related Groups","mj":false,"qs":[{"q":"standards","mj":true,"ui":"Q000592"}],"ui":"D003953"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Medication Reconciliation","mj":false,"qs":[{"q":"standards","mj":true,"ui":"Q000592"},{"q":"trends","mj":false,"ui":"Q000639"}],"ui":"D059065"},{"d":"Neuromyelitis Optica","mj":false,"qs":[{"q":"diagnosis","mj":true,"ui":"Q000175"},{"q":"therapy","mj":true,"ui":"Q000628"}],"ui":"D009471"}],"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://link.springer.com/content/pdf/10.1007/s00415-013-7169-7.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/b5523c34aceaf17051ae0bbbdfcf7f98e3b12b98","s2_open_access_license":"CCBY","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Abstract\nNeuromyelitis optica (NMO, Devic’s syndrome), long considered a clinical variant of multiple sclerosis, is now regarded as a distinct disease entity. Major progress has been made in the diagnosis and treatment of NMO since aquaporin-4 antibodies (AQP4-Ab; also termed NMO-IgG) were first described in 2004. In this review, the Neuromyelitis Optica Study Group (NEMOS) summarizes recently obtained knowledge on NMO and highlights new developments in its diagnosis and treatment, based on current guidelines, the published literature and expert discussion at regular NEMOS meetings. Testing of AQP4-Ab is essential and is the most important test in the diagnostic work-up of suspected NMO, and helps to distinguish NMO from other autoimmune diseases. Furthermore, AQP4-Ab testing has expanded our knowledge of the clinical presentation of NMO spectrum disorders (NMOSD). In addition, imaging techniques, particularly magnetic resonance imaging of the brain and spinal cord, are obligatory in the diagnostic workup. It is important to note that brain lesions in NMO and NMOSD are not uncommon, do not rule out the diagnosis, and show characteristic patterns. Other imaging modalities such as optical coherence tomography are proposed as useful tools in the assessment of retinal damage. Therapy of NMO should be initiated early. Azathioprine and rituximab are suggested as first-line treatments, the latter being increasingly regarded as an established therapy with long-term efficacy and an acceptable safety profile in NMO patients. Other immunosuppressive drugs, such as methotrexate, mycophenolate mofetil and mitoxantrone, are recommended as second-line treatments. Promising new therapies are emerging in the form of anti-IL6 receptor, anti-complement or anti-AQP4-Ab biologicals.","claims":[{"public_id":"cl_199f18f1e5cf1c25e508a714d29dec20","status":"active","text":"Aquaporin-4 antibody testing is the most important diagnostic test in suspected neuromyelitis optica and helps distinguish it from other autoimmune diseases.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_199f18f1e5cf1c25e508a714d29dec20"},{"public_id":"cl_7e0d7e49fba033332de51522b57b39ee","status":"active","text":"Early initiation of therapy is recommended, with azathioprine and rituximab suggested as first-line treatments and methotrexate, mycophenolate mofetil, and mitoxantrone recommended as second-line treatments.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7e0d7e49fba033332de51522b57b39ee"},{"public_id":"cl_d7be21ff302587e8e0f5eba207eeed1a","status":"active","text":"Magnetic resonance imaging of the brain and spinal cord is obligatory in the diagnostic work-up, and brain lesions in neuromyelitis optica and neuromyelitis optica spectrum disorders do not rule out the diagnosis.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d7be21ff302587e8e0f5eba207eeed1a"},{"public_id":"cl_3fbc5def3d9096a0e93b8833ea4e77bb","status":"active","text":"Optical coherence tomography is proposed as a useful tool for assessing retinal damage.","confidence":0.88,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_3fbc5def3d9096a0e93b8833ea4e77bb"},{"public_id":"cl_2cc2e0614b45ed5cdb450e70d32af29d","status":"active","text":"Rituximab is increasingly regarded as an established therapy with long-term efficacy and an acceptable safety profile in neuromyelitis optica patients.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2cc2e0614b45ed5cdb450e70d32af29d"}],"concepts":[{"public_id":"co_049fba9ee226520639ab8056aec17be9","status":"active","name":"safety profile","description":"The pattern and acceptability of adverse effects associated with a treatment.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_049fba9ee226520639ab8056aec17be9"},{"public_id":"co_1b652713e5e5c50f7301964ffc38d5bd","status":"active","name":"magnetic resonance imaging","description":"An imaging modality used to assess the brain and spinal cord in neuromyelitis optica.","types":["imaging modality"],"aliases":["MRI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1b652713e5e5c50f7301964ffc38d5bd"},{"public_id":"co_261600116dddd708f9f49aaf068661ab","status":"active","name":"rituximab","description":"A monoclonal antibody used as an immunotherapy for neuromyelitis optica.","types":["drug","biological therapy"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_261600116dddd708f9f49aaf068661ab"},{"public_id":"co_32644473dc08f6c2e0dcfd28a20146d7","status":"active","name":"retinal damage","description":"Damage to the retina that can be assessed with ocular imaging.","types":["pathology"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_32644473dc08f6c2e0dcfd28a20146d7"},{"public_id":"co_3380b2cc3d58baa91a963b2dcdece9a4","status":"active","name":"diagnostic work-up","description":"The set of tests and imaging studies used to evaluate suspected neuromyelitis optica.","types":["diagnostic process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3380b2cc3d58baa91a963b2dcdece9a4"},{"public_id":"co_36956381dd0686ef36a296c306e186f6","status":"active","name":"long-term efficacy","description":"Sustained treatment benefit over an extended follow-up period.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_36956381dd0686ef36a296c306e186f6"},{"public_id":"co_3757b35b5b86195381ed1a381c76f4b6","status":"active","name":"neuromyelitis optica spectrum disorders","description":"A broader clinical spectrum that includes neuromyelitis optica and related presentations.","types":["disease spectrum"],"aliases":["NMOSD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3757b35b5b86195381ed1a381c76f4b6"},{"public_id":"co_56358792e74b56497844bbe5c7cd73f4","status":"active","name":"brain lesions","description":"Structural abnormalities in the brain observed in neuromyelitis optica and related disorders.","types":["imaging finding"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_56358792e74b56497844bbe5c7cd73f4"},{"public_id":"co_5fef32a6a267b809eaf0340dac0b3aaa","status":"active","name":"optical coherence tomography","description":"An imaging technique used to evaluate retinal structure and damage.","types":["imaging modality"],"aliases":["OCT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5fef32a6a267b809eaf0340dac0b3aaa"},{"public_id":"co_accaec3f78adf875713aff2cb24f15f9","status":"active","name":"second-line treatments","description":"Therapies used when first-line treatment options are not sufficient or appropriate.","types":["treatment category"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_accaec3f78adf875713aff2cb24f15f9"},{"public_id":"co_adb174bb6be19f4543628c073023af6b","status":"active","name":"neuromyelitis optica","description":"A distinct inflammatory demyelinating disease of the central nervous system also known as Devic’s syndrome.","types":["disease"],"aliases":["NMO","Devic’s syndrome"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_adb174bb6be19f4543628c073023af6b"},{"public_id":"co_af5ebefa2411fb68678607742fb4152f","status":"active","name":"aquaporin-4 antibodies","description":"Autoantibodies against the aquaporin-4 water channel used in the diagnosis of neuromyelitis optica.","types":["biomarker","antibody"],"aliases":["AQP4-Ab","NMO-IgG"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_af5ebefa2411fb68678607742fb4152f"},{"public_id":"co_ea84fcf6f4562463961667d7f2494f2f","status":"active","name":"azathioprine","description":"An immunosuppressive drug suggested as a first-line treatment for neuromyelitis optica.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ea84fcf6f4562463961667d7f2494f2f"}],"external_ids":{"DOI":"10.1007/s00415-013-7169-7","ArXiv":null,"PubMed":24272588,"PubMedCentral":"3895189","MAG":2038941725,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://link.springer.com/content/pdf/10.1007/s00415-013-7169-7.pdf","landing_url":"https://www.semanticscholar.org/paper/b5523c34aceaf17051ae0bbbdfcf7f98e3b12b98","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631608,"paper_uid":"e4556bf2-f8f7-4b13-99cf-1371859f28ca","canonical_identity":{"paper_id":631608,"paper_uid":"e4556bf2-f8f7-4b13-99cf-1371859f28ca","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/1215691"}